Halozyme Therapeutics's revenue for the
three
months ended in Dec. 2023 was $230.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $829.3 Mil.
Halozyme Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $1.76.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $6.20.
During the past 12 months, the average Revenue per Share Growth Rate of Halozyme Therapeutics was 31.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 48.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 45.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 24.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Halozyme Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 232.20% per year. The lowest was -6.00% per year. And the median was 41.60% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Halozyme Therapeutics's Revenue
For the Biotechnology subindustry, Halozyme Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Revenue falls into.
Halozyme Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $829.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Halozyme Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Halozyme Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Halozyme Therapeutics (Halozyme Therapeutics) Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HALO has been successfully added to your 